ACVR2A activin A receptor type 2A
ENSG00000121989 · protein coding · Open Targets profile
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A (PubMed:17911401, PubMed:10652306). Mediates induction of adipogenesis by GDF6 (By similarity). {ECO:0000250|UniProtKB:P27038, ECO:0000269|PubMed:1314589, ECO:0000269|PubMed:17911401}.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.11399000138044357 (upper bound 0.21410000324249268). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 13 registry trials, updated in the last three years, of the most advanced drugs against ACVR2A (dibotermin alfa), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Matthew GreivesThe University of Texas Health Science Center, Houston · 1 of 1 trials Phase 2+
- Diel PeterOrthopädie Sonnenhof, Bern · 0 of 1 trials Phase 2+
- Jumi HanCGBio Inc. · 0 of 1 trials Phase 2+
- Peter PassiasNYU Langone Medical Center · 0 of 1 trials Phase 2+
- Wenjie RenThe First Affiliated Hospital of Xinxiang Medical College · 0 of 1 trials Phase 2+
Registry trials of dibotermin alfa updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 9 of 11 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
11 trials of drugs against ACVR2A were stopped early; 4 give no reason
Terminated, withdrawn and suspended interventional trials of dibotermin alfa, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 11 most recent of 11.
- terminated · 2023-05-17 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2023-05-17 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- withdrawn · 2022-11-14 · Ross Leighton · matched by the registry's drug synonyms“Study never started”
- terminated · 2021-10-27 · University of Alabama at Birmingham · matched by the registry's drug synonyms“Insufficient enrollment to meet the statistical requirements”
- terminated · 2019-08-28 · Virtua Health, Inc. · matched by the registry's drug synonyms“PI left the institution”
- terminated · 2018-10-25 · St. Louis University · matched by the registry's drug synonyms“Enrollment too slow”
- withdrawn · 2018-09-13 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2016-02-18 · Medtronic Spinal and Biologics · matched by the registry's drug synonyms“Due to study design challenges including DMC enrollment suspension as required by the protocol stopping rules and recommended changes to the surgical technique”
- terminated · 2015-01-21 · Medtronic Spinal and Biologics · matched by the registry's drug synonyms“Difficulty in patient recruitment”
- terminated · 2013-08-02 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2013-02-28 · Wyeth is now a wholly owned subsidiary of Pfizer · matched by the registry's drug synonyms“Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate enrollment but complete follow-up).”
Paediatric incentives and obligations for ACVR2A's drugs
For dibotermin alfa: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · ACVR2A is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names dibotermin alfaRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names dibotermin alfaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Inductos: authorised since 9 Sept 2002Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Inductos, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of dibotermin alfaRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 6 interventional studies of dibotermin alfa include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 1 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| DIBOTERMIN ALFA | Protein | phase 4 | spinal fusion, tibia fracture, bone disorder, osteoporosis | Open Targets · ChEMBL |